Befejeződött4. fázis
A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
A legfontosabb adatok
- Ki végzi
- GlaxoSmithKline
- Hol
- India5 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 4. fázis
- Résztvevők
- 250 fő vett részt
- Kezdés
- 2023. dec. 14.
- Befejezés
- 2024. febr. 26.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Fluarix Tetra Vaccine
- A regiszteradat frissítve
- 2025. március 28.
Ki vehet részt
- Életkor
- 65 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female participants aged >= 65 years of age
- Participants and/or legally acceptable representative (s) (LAR) who in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits
- Written or witnessed/thumb printed informed consent obtained from the participant and/or participant's LAR(s) after the study has been explained according to the local authority requirements and prior to performance of any study-specific procedure
Ki nem vehet részt
- History of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
- Receipt of licensed vaccine, immune sera and/or any blood products, or an investigational trial agent within previous 30 days or planned during their participation in the trial
- Receipt of any flu vaccine within 6 months before trial start or any other vaccine within 30 days before the trial
- Altered immune status or chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents within six months prior to administration of trial vaccine
- History of acute infectious disease or acute respiratory illness needing antibiotics or antivirals in the previous 7 days, based on investigator's judgement
- Receipt of any dose of a Coronavirus Disease 2019 (COVID-19) vaccine within 15 days of trial start
- History of Guillain-Barré Syndrome
- Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the trial
- Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination, or laboratory screening tests
- If a participant candidate has fever, the trial vaccination should be postponed to when the fever has resolved for at least 2 days (temporary exclusion criterion). Fever is defined as temperature >=38.0 degree Celsius (°C) (100.4 degrees Fahrenheit [°F]) by any route. The preferred location for measuring temperature will be oral route
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter [mL]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a post-approval condition imposed by the Indian regulatory authorities (CDSCO) for this age group in India.
A vizsgálat csoportja
- Quadrivalent seasonal influenza (FLU D-QIV) vaccine groupA vizsgált kezelés
Participants received 1 dose of seasonal FLU vaccine at Day 1.
Kezelés: Fluarix Tetra Vaccine
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Single-arm, Open-label, Multi-center, Phase IV Trial to Evaluate the Reactogenicity, Safety, and Immunogenicity of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
- Publikációk
- A regiszteradat frissítve
- 2025. március 28.